MX2018010535A - Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona. - Google Patents
Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona.Info
- Publication number
- MX2018010535A MX2018010535A MX2018010535A MX2018010535A MX2018010535A MX 2018010535 A MX2018010535 A MX 2018010535A MX 2018010535 A MX2018010535 A MX 2018010535A MX 2018010535 A MX2018010535 A MX 2018010535A MX 2018010535 A MX2018010535 A MX 2018010535A
- Authority
- MX
- Mexico
- Prior art keywords
- piridazin
- dihidro
- ona
- phenyl
- methyl
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000005156 substituted alkylene group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención proporciona un agente para tratar un tumor maligno, que comprende un compuesto de formula (1): (ver formula I) donde R1 a R4 son un átomo de hidrogeno, halógeno o etc., Y es un grupo alquileno opcionalmente sustituido o etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016042535 | 2016-03-04 | ||
| PCT/JP2017/008246 WO2017150654A1 (en) | 2016-03-04 | 2017-03-02 | 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010535A true MX2018010535A (es) | 2019-01-10 |
| MX377854B MX377854B (es) | 2025-03-11 |
Family
ID=58347859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010535A MX377854B (es) | 2016-03-04 | 2017-03-02 | Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10611731B2 (es) |
| EP (1) | EP3423440B9 (es) |
| JP (1) | JP6596595B2 (es) |
| KR (1) | KR102350772B1 (es) |
| CN (1) | CN108779076B (es) |
| AU (2) | AU2017226674B2 (es) |
| CY (1) | CY1123927T1 (es) |
| DK (1) | DK3423440T3 (es) |
| EA (1) | EA036423B1 (es) |
| ES (1) | ES2862177T3 (es) |
| HR (1) | HRP20210395T1 (es) |
| HU (1) | HUE053358T2 (es) |
| IL (1) | IL261225B (es) |
| LT (1) | LT3423440T (es) |
| MX (1) | MX377854B (es) |
| MY (1) | MY196801A (es) |
| NZ (1) | NZ745688A (es) |
| PH (1) | PH12018501873B1 (es) |
| PL (1) | PL3423440T3 (es) |
| PT (1) | PT3423440T (es) |
| RS (1) | RS61593B1 (es) |
| SA (1) | SA518392275B1 (es) |
| SG (1) | SG11201807146SA (es) |
| SI (1) | SI3423440T1 (es) |
| SM (1) | SMT202100138T1 (es) |
| TW (1) | TWI731041B (es) |
| WO (1) | WO2017150654A1 (es) |
| ZA (1) | ZA201805791B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7104588B2 (ja) * | 2017-09-01 | 2022-07-21 | 大塚製薬株式会社 | ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤 |
| TWI750573B (zh) * | 2019-02-01 | 2021-12-21 | 德商拜耳廠股份有限公司 | 1,2,4-三-3(2h)-酮化合物 |
| KR20260006625A (ko) | 2023-05-08 | 2026-01-13 | 오츠카 세이야쿠 가부시키가이샤 | 거대핵세포 분화 및 성숙의 억제제 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63145272A (ja) * | 1986-12-09 | 1988-06-17 | Morishita Seiyaku Kk | ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体 |
| US5100892A (en) | 1990-11-13 | 1992-03-31 | Glaxo Inc. | Dihydropyridine vasodilator agents |
| US5563143A (en) * | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| CN1136197C (zh) * | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
| CA2588949A1 (en) * | 2004-11-30 | 2006-06-08 | Artesian Therapeutics, Inc. | Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
| EP2168959A1 (en) | 2007-06-19 | 2010-03-31 | Kyorin Pharmaceutical Co., Ltd. | Pyridazinone derivative and pde inhibitor containing the same as active ingredient |
| CN101537006B (zh) * | 2008-03-18 | 2012-06-06 | 中国科学院上海药物研究所 | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 |
| US9890127B2 (en) | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
-
2017
- 2017-03-02 CN CN201780013870.4A patent/CN108779076B/zh active Active
- 2017-03-02 MY MYPI2018703021A patent/MY196801A/en unknown
- 2017-03-02 JP JP2018544577A patent/JP6596595B2/ja active Active
- 2017-03-02 TW TW106106813A patent/TWI731041B/zh active
- 2017-03-02 PL PL17711366T patent/PL3423440T3/pl unknown
- 2017-03-02 SM SM20210138T patent/SMT202100138T1/it unknown
- 2017-03-02 RS RS20210193A patent/RS61593B1/sr unknown
- 2017-03-02 MX MX2018010535A patent/MX377854B/es unknown
- 2017-03-02 KR KR1020187028010A patent/KR102350772B1/ko active Active
- 2017-03-02 ES ES17711366T patent/ES2862177T3/es active Active
- 2017-03-02 LT LTEP17711366.9T patent/LT3423440T/lt unknown
- 2017-03-02 EP EP17711366.9A patent/EP3423440B9/en active Active
- 2017-03-02 SG SG11201807146SA patent/SG11201807146SA/en unknown
- 2017-03-02 PH PH1/2018/501873A patent/PH12018501873B1/en unknown
- 2017-03-02 NZ NZ745688A patent/NZ745688A/en unknown
- 2017-03-02 DK DK17711366.9T patent/DK3423440T3/da active
- 2017-03-02 EA EA201891987A patent/EA036423B1/ru not_active IP Right Cessation
- 2017-03-02 PT PT177113669T patent/PT3423440T/pt unknown
- 2017-03-02 WO PCT/JP2017/008246 patent/WO2017150654A1/en not_active Ceased
- 2017-03-02 SI SI201730668T patent/SI3423440T1/sl unknown
- 2017-03-02 US US16/081,260 patent/US10611731B2/en active Active
- 2017-03-02 HU HUE17711366A patent/HUE053358T2/hu unknown
- 2017-03-02 HR HRP20210395TT patent/HRP20210395T1/hr unknown
- 2017-03-02 AU AU2017226674A patent/AU2017226674B2/en active Active
-
2018
- 2018-08-19 IL IL261225A patent/IL261225B/en unknown
- 2018-08-26 SA SA518392275A patent/SA518392275B1/ar unknown
- 2018-08-29 ZA ZA2018/05791A patent/ZA201805791B/en unknown
-
2020
- 2020-02-12 US US16/788,894 patent/US20200181092A1/en not_active Abandoned
-
2021
- 2021-02-22 AU AU2021201135A patent/AU2021201135B2/en active Active
- 2021-02-23 US US17/182,549 patent/US20210171472A1/en not_active Abandoned
- 2021-02-24 CY CY20211100155T patent/CY1123927T1/el unknown
-
2024
- 2024-08-08 US US18/798,284 patent/US20240400520A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17005635A (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
| CU24572B1 (es) | Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas | |
| CO2017002191A2 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| SA523440283B1 (ar) | مركبات مضادة للأورام | |
| EA201890648A2 (ru) | Диоксолановые аналоги уридина для лечения рака | |
| EA201991580A1 (ru) | Пиримидиновое соединение и его фармацевтическое применение | |
| EA201792287A1 (ru) | Способы лечения рака | |
| MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| JOP20190073A1 (ar) | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| BR112016002638A2 (pt) | novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2018010535A (es) | Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona. | |
| EA201792288A1 (ru) | Способы лечения рака | |
| EA202190045A1 (ru) | Составы/композиции, содержащие ибрутиниб | |
| BR112017014679A2 (pt) | composto de carbamato, seu uso, agente controlador de doenças de plantas e método para controlar doenças de plantas | |
| MX380776B (es) | Derivados de pirazolilaminobenzimidazol como inhibidores de jak. | |
| PL411196A1 (pl) | Nowe funkcjonalizowane nienasycone pochodne (dimetylowinylogermoksy) heptapodstawionych silseskwioksanów oraz sposób ich otrzymywania | |
| AR109322A1 (es) | Tratamiento de tumores sólidos refractarios y/o reincidente y linfomas no hodgkin | |
| PL417754A1 (pl) | Sole poli(5-amino-2-hydroksy-N,N-dimetylo-5-(metyloamino)pentan-1-amoniowe oraz sposób ich otrzymywania |